DOCSLIB.ORG

7 (1A) - N-27 (1B) Patent Application Publication Dec

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
7 (1A) - N-27 (1B) Patent Application Publication Dec US 20080299.199A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0299199 A1 Bar-Shalom et al. (43) Pub. Date: Dec. 4, 2008 (54) SWELLABLE DOSAGE FORM COMPRISING Publication Classification GELLAN GUMI (51) Int. Cl. A6II 47/36 (2006.01) (75) Inventors: Daniel Bar-Shalom, Kokkedal A6II 47/38 (2006.01) (DK); Lillian Slot, Virum (DK); A6II 47/32 (2006.01) Gina Fischer, Vaerlose (DK); A6II 47/02 (2006.01) Pernille Hoyrup Hemmingsen, A6IR 9/00 (2006.01) Bagsvaerd (DK) (52) U.S. Cl. ......... 424/484: 514/777: 514/779; 514/781; 424/400: 514/772.4: 514/769 Correspondence Address: (57) ABSTRACT FOLEY AND LARDNER LLP SUTESOO A novel dosage form. The dosage form is presented in par 3OOOK STREET NW ticulate form and before oral ingestion the particulate mate WASHINGTON, DC 20007 (US) rial is subjected to an aqueous medium, whereby it is con Verted to a semi-solid form by Swelling or gelling of one or (73) Assignee: Egalet a?s more of the components, especially of a gellan gum, of the particulate matter. The invention also relates to a vehicle for oral administration of one or more active Substances, the (21) Appl. No.: 111596,123 vehicle comprising a gellan gum arranged in a configuration allowing optimal water diffusion so that upon addition of a (22) PCT Filed: May 11, 2005 predetermined amount of an aqueous medium, without the necessity of applying shear forces or other mixing forces, (86). PCT No.: PCT/DKOS/OO317 within a time period of 5 minutes or less swells and/or gels and the texture of the swelled vehicle being similar to that of S371 (c)(1), a soft pudding and having a viscosity of at least about 10,000 (2), (4) Date: Aug. 14, 2007 cps as measured by a Brookfield Viscometer with a #4 LV spindle at 6 rpm and at 20-25°C. In one embodiment of the (30) Foreign Application Priority Data invention, the particulate matter can be moulded into a desired shape or pressed onto a dispensing unit such as a May 11, 2004 (DK) ........................... PA 2004 OO755 Spoon. (1) \-7 (1a) - N-27 (1b) Patent Application Publication Dec. 4, 2008 Sheet 1 of 10 US 2008/0299.199 A1 Patent Application Publication Dec. 4, 2008 Sheet 2 of 10 US 2008/0299.199 A1 Dissolution of 200 mg Paracetamol parvulet 120 - - - -0-61% coated 100 Paracetamol -- 200 mg Paracetamol 80 parvulet -A-200 mg Paracetamol ?a parvulet SSo 60 -X-200 mg Paracetamol 40 parvulet -- 200 mg Paracetamol parvulet 20 -e-200 mg Paracetamol parvulet O - O 5 10 15 20 25 30 35 40 45 50 55 time min Fig. 2 Patent Application Publication Dec. 4, 2008 Sheet 3 of 10 US 2008/0299.199 A1 Patent Application Publication Dec. 4, 2008 Sheet 4 of 10 US 2008/0299.199 A1 jeg Fig. 4 Patent Application Publication Dec. 4, 2008 Sheet 5 of 10 US 2008/0299.199 A1 Patent Application Publication Dec. 4, 2008 Sheet 6 of 10 US 2008/0299.199 A1 Patent Application Publication Dec. 4, 2008 Sheet 7 of 10 US 2008/0299.199 A1 Fig. 7 Patent Application Publication Dec. 4, 2008 Sheet 8 of 10 US 2008/0299.199 A1 F8 i sts' Ea 8 & s 3.s; : :3. S8. 8 3. Fig. 8 Patent Application Publication Dec. 4, 2008 Sheet 9 of 10 US 2008/0299.199 A1 20 — 100 8 O --Wessel 1 -H-Wessel 2 -A-Wessel 3 re-vessel 4 --vesses se-Wessel 6 4. o 2 O 0 10 20 30 4. 50 SO 70 Time (min) Fig. 9 Patent Application Publication Dec. 4, 2008 Sheet 10 of 10 US 2008/0299.199 A1 US 2008/0299.199 A1 Dec. 4, 2008 SWELLABLE DOSAGE FORM COMPRISING then be formulated into tablets or capsules meant to be swal GELLAN GUMI lowed whole. Those tablets and capsules as Such are inappro priate for patients with Swallowing difficulties. Patients (or FIELD OF THE INVENTION they providers in the case of children) are often instructed to open the capsules (or crush the tablets) and to sprinkle the 0001. The present application relates to a novel dosage powder on syrup or pudding or applesauce or similar and then form. The dosage form is presented in particulate form and administered. This approach has limitations. The carrier before oral ingestion the particulate material is subjected to (syrup, pudding, applesauce) is not a well defined entity and an aqueous medium, whereby it is converted to a semi-solid different carriers might interact differently with the multi form by Swelling or gelling of one or more of the components, particles and/or drug and thereby compromise the treatment. especially of a gellan gum, of the particulate matter. The Also, children might object to the grittiness in the material. invention also relates to a vehicle for oral administration of Syrups do not necessarily resemble types of food or bever one or more active Substances, the vehicle comprising a gel ages that children are used to consume. langum arranged in a configuration allowing optimal water 0005. Alternatively the powder can be formulated into diffusion so that upon addition of a predetermined amount of effervescent granules or tablets. These granules or tablets are an aqueous medium, without the necessity of applying shear intended to be dissolved in an aqueous liquid requiring the forces or other mixing forces, within a time period of 5 provision of a glass of liquid and a waiting period sufficient to minutes or less swells and/or gels and the texture of the allow the tablet to completely dissolve and the resulting vol swelled vehicle being similar to that of a soft pudding and ume might be considerable. Often, these dosage forms leave having a viscosity of at least about 10,000 cps as measured by an objectionable deposit in the glass, which may represent a a BrookfieldViscometer with a #4 LV spindle at 6 rpm and at non-ingested part of the drug. Effervescent formulations are, 20-250 C. in general more appropriate for adults although some com 0002. In one embodiment of the invention, the particulate mercial vitamin preparations for children use this approach. matter can be moulded into a desired shape or pressed onto a 0006 Another category is the fast-melting tablets meant to dispensing unit Such as a spoon. be put on the tongue and disintegrate upon contact with saliva. The might be effervescent or non-effervescent. Yet another BACKGROUND OF THE INVENTION Solution is to dispense the multi-particles in lozenges, chew 0003. A recurring problem in the treatment of patients, in able tablets and chewing gum. particular children and the elderly, is their inability or unwill 0007. One example of these approaches was described in ingness to Swallow solid oral dosage forms such as tablets or Wehling et al., U.S. Pat. No. 5,178.878, which relates to capsules. The problem is, however, not uncommon in healthy certain effervescent dosage forms including microparticles. adults as well. This problem is not trivial, the inability or The effervescent dosage forms of Wehling et al. provide a unwillingness of some people to take Solid oral dosage forms significant advance over the art in that they provide an effer can severely compromise the patient's compliance with a Vescent dosage form for direct oral administration. The dos prescribed treatment protocol. Moreover, due to embarrass age form is designed to disintegrate rapidly in the mouth ment, many patients are unwilling to tell their doctor of their releasing its microparticles as a slurry for ingestion. The problem so that the doctor can consider other drugs and/or dosage forms produced in accordance with Wehling et al. can alternate dosage forms. Such a lack of compliance can com be placed in the patient's mouth and the effervescence con promise treatment or cure. tained therein will be activated by contact with the patient’s 0004 Ifan orally administered drug has such a taste that is saliva. The tablet will then disintegrate in a number of sec acceptable to the patient and the pharmacokinetic character onds. However, the effervescence on the tongue may be istics allow reasonable administration regimens, such as once unpleasant to Some adults and to many children. or twice daily, the drug might be formulated in a sirup, elixir, 0008 Kallstrand, et al., U.S. Pat. No. 4,994.260 relates to Suspension or other liquid dosage forms. Unfortunately, in a pharmaceutical mixture. The mixture is used for the con many cases the native taste of the drug is unpleasant and not trolled release of a Substance. According to Kallstrand et al., amenable to taste-masking by the addition of Sweeteners of a liquid dosage form is produced using either a dry powder or flavours. Also, many drugs have such pharmacokinetic microcapsules, which are Suspended in a solution of a release parameters that demand administration at short intervals, dis controlling Substance, also referred to as a "sink. Alterna rupting sleep and other activities. The taste and/or pharma tively, it is possible to encapsulate the release-controlling cokinetic deficiencies can be corrected by the use of various Substance, together with a drug, within an encapsulating coating and/or matrices and/or by modifying the crystalline shell. The release-controlling Substance may include, inter structure, etcetera. U.S. Pat. No. 6,589,955 illustrates such an alia, carbohydrates and carbohydrate-related compounds, approach. The resulting material after micro-encapsulation or disaccharides, monosaccharides, glycerol, glycol, glycosides crystallization or other strategies might be a monolithical of monosaccharides and Substances derived from ethyleneg unit, one unit containing the whole dose, or multi-particles, lycol.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • A Small Outbreak of Third Generation Cephem-Resistant Citrobacter
    Jpn. J. Infect. Dis., 57, 2004 Laboratory and Epidemiology Communications A Small Outbreak of Third Generation Cephem-Resistant Citrobacter freundii Infection on a Surgical Ward Toshi Nada*, Hisashi Baba, Kumiko Kawamura2, Teruko Ohkura, Keizo Torii1 and Michio Ohta1 Department of Clinical Laboratory, Nagoya University Hospital, Nagoya 466-8560, 1Department of Bacteriology, Nagoya University Graduate School of Medicine, Nagoya 466-8550 and 2Department of Medical Technology, Nagoya University School of Health Sciences, Nagoya 461-8673 Communicated by Yoshichika Arakawa (Accepted June 11, 2004) Citrobacter freundii is a member of family Enterobacteri- from those of type a and b strains. aceae and has been associated with nosocomial infections As previous studies have indicated, third generation in the urinary, respiratory, and biliary tracts of debilitated cephem-resistance of Gram-negative bacteria are due to the hospital patients. C. freundii has an inducible chromosomally hydrolysis of β-lactams by β-lactamases. These β-lactamases encoded cephalosporinase that can inactivate cephamycins include extended spectrum β-lactamase (ESBL), metallo- and cephalosporins. However, most clinical isolates are β-lactamase, and plasmid-encoded AmpC cephalosporinase sensitive to new third generation cephems and carbapenems. (1-3). ESBL confers variable levels of resistance to cefotaxime, We report here a small outbreak of infection caused by ceftazidime, and other broad-spectrum cephalosporins and third generation cephem-resistant C. freundii on a surgical to monobactams, but has no detectable activity against ward of a university hospital in 2002. We identified four cephamycins and carbapenems, and is relatively sensitive patients with biliary infection and two carrier patients during to sulbactam (1). Plasmid-encoded metallo-β-lactamase July and October.
    [Show full text]
  • Sepsis Caused by Newly Identified Capnocytophaga Canis Following Cat Bites: C
    doi: 10.2169/internalmedicine.9196-17 Intern Med 57: 273-277, 2018 http://internmed.jp 【 CASE REPORT 】 Sepsis Caused by Newly Identified Capnocytophaga canis Following Cat Bites: C. canis Is the Third Candidate along with C. canimorsus and C. cynodegmi Causing Zoonotic Infection Minami Taki 1, Yoshio Shimojima 1, Ayako Nogami 2, Takuhiro Yoshida 1, Michio Suzuki 3, Koichi Imaoka 3, Hiroki Momoi 1 and Norinao Hanyu 1 Abstract: Sepsis caused by a Capnocytophaga canis infection has only been rarely reported. A 67-year-old female with a past medical history of splenectomy was admitted to our hospital with fever and general malaise. She had been bitten by a cat. She showed disseminated intravascular coagulation and multi-organ failure because of severe sepsis. On blood culture, characteristic gram-negative fusiform rods were detected; therefore, a Capnocytophaga species infection was suspected. A nucleotide sequence analysis revealed the species to be C. canis, which was newly identified in 2016. C. canis may have low virulence in humans; however, C. canis with oxidase activity may cause severe zoonotic infection. Key words: Capnocytophaga canis, Capnocytophaga canimorsus, sepsis, oxidase activity (Intern Med 57: 273-277, 2018) (DOI: 10.2169/internalmedicine.9196-17) Introduction Case Report The genus Capnocytophaga consists of gram-negative A 67-year-old woman was admitted to our hospital with rod-shaped bacteria that reside in the oral cavities of humans general malaise and fever for 3 days starting the day after and domestic animals. Capnocytophaga formerly comprised being bitten by a cat on both her hands. She had a medical eight species (1, 2).
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Product Information
    ATROPINE INJECTION BP (Atropine sulfate monohydrate) 1. NAME OF THE MEDICINE Atropine sulfate monohydrate 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Atropine Injection BP is a sterile, isotonic, preservative free solution containing 600 microgram of atropine sulfate monohydrate in 1 mL or 1.2 mg of atropine sulfate monohydrate in 1 mL. 3. PHARMACEUTICAL FORM Solution for injection 4. CLINICAL PARTICULARS 4.1 Therapeutic Indications Preanaesthetic medication to reduce salivary secretions and bronchial secretions to prevent cholinergic cardiac effects such as cardiac arrhythmias, hypotension and bradycardia management of patients with acute myocardial infarction and sinus bradycardia who have associated hypotension and increased ventricular irritability concurrent administration with anticholinesterase agents (e.g. neostigmine, physostigmine) to block the adverse muscarinic effects of these agents following surgery to terminate curarisation for poisoning by organophosphate pesticides, atropine may be used concomitantly with a cholinesterase reactivator such as pralidoxime to reverse muscarinic effects. 4.2 Dose and Method of Administration Atropine Injection may be given by subcutaneous (SC), intramuscular (IM) or direct intravenous (IV) injection. Atropine Injection should not be added to any IV infusion solutions for administration. Atropine Injection contains no microbial agent. It should be used only once and any residue discarded. Cardiopulmonary resuscitation The usual adult dose is 0.4 - 1 mg IV, which may be repeated at 5 minute intervals until the desired heart rate is achieved. The total dose should not exceed 2 mg. Page 1 of 11 The usual paediatric dose is 0.02 mg/kg (maximum single dose 0.5 mg) IV, which may be repeated at 5 minute intervals until the desired heart rate is achieved.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • B-Lactams: Chemical Structure, Mode of Action and Mechanisms of Resistance
    b-Lactams: chemical structure, mode of action and mechanisms of resistance Ru´ben Fernandes, Paula Amador and Cristina Prudeˆncio This synopsis summarizes the key chemical and bacteriological characteristics of b-lactams, penicillins, cephalosporins, carbanpenems, monobactams and others. Particular notice is given to first-generation to fifth-generation cephalosporins. This review also summarizes the main resistance mechanism to antibiotics, focusing particular attention to those conferring resistance to broad-spectrum cephalosporins by means of production of emerging cephalosporinases (extended-spectrum b-lactamases and AmpC b-lactamases), target alteration (penicillin-binding proteins from methicillin-resistant Staphylococcus aureus) and membrane transporters that pump b-lactams out of the bacterial cell. Keywords: b-lactams, chemical structure, mechanisms of resistance, mode of action Historical perspective Alexander Fleming first noticed the antibacterial nature of penicillin in 1928. When working with Antimicrobials must be understood as any kind of agent another bacteriological problem, Fleming observed with inhibitory or killing properties to a microorganism. a contaminated culture of Staphylococcus aureus with Antibiotic is a more restrictive term, which implies the the mold Penicillium notatum. Fleming remarkably saw natural source of the antimicrobial agent. Similarly, under- the potential of this unfortunate event. He dis- lying the term chemotherapeutic is the artificial origin of continued the work that he was dealing with and was an antimicrobial agent by chemical synthesis [1]. Initially, able to describe the compound around the mold antibiotics were considered as small molecular weight and isolates it. He named it penicillin and published organic molecules or metabolites used in response of his findings along with some applications of penicillin some microorganisms against others that inhabit the same [4].
    [Show full text]
  • Antibiotics and Antibacterials, General
    B. Sulfamethoxydiazine (Sulfameter, Sulla) IX. TOXICITY AND SIDE EFFECTS: C. Sulfadimethoxine (Madribon) A. Fever D. Sulphormethoxine-Very long-acting; thera- B. Rash, urticaria peutic blood levels for 1 week. C. Cyanosis, methemoglobinemia D. Nausea, vomiting, diarrhea V. POORLY ABSORBED SULFONAMIDES: E. Hepatitis, jaundice for local use in the intestinal tract only. F. Hematuria, albuminuria, crystalluria, toxic A. Succinylsulfathiazole (Sulfasuxidine): nephritis. 1. Dosage-3.0 Gm q 4 h p.o. G. Headache, mental depression, psychosis, 2. Maximum effect usually not achieved un- peripheral neuritis. til 7th day of therapy. H. Leukopenia, agranulocytosis, purpura, aplas- B. Phthalylsulfathiazole (Sulfathalidine): tic anemia, hypoprothrombinemia, hemolytic ane- 1. Dosage-1.5 Gmq4hp.o. mia. 2. Double this dosage in the presence of I. Severe hypersensitivity reactions - anaphy- diarrhea. laxis, periarteritis nodosa and other collagen dis- 3. Effect produced in 5-7 days. eases, Stevens-Johnson syndrome. C. Para-nitrosulfathiazole (Nisulfazole): Used X. only for intrarectal instillation in treatment of PRECAUTIONS: proctitis or non-specific colitis. A. Keep careful record of urine output - try to maintain output of at least 1200-1500 ml/24 VI. TOPICAL SULFONAMIDES: hrs. B. Alkalinization of urine-sodium bicarbonate A. Mafenide (Sulfamylon): Used on skin as (12-15 Gm/day) may be used for this purpose 10% cream. Unlike other sulfonamides, effective when full systemic doses of sulfonamides are used, in presence of pus and necrotic tissue and does not when there is difficulty in being sure of adequate sensitize readily when used topically. Of value in fluid intake and output, and when such adjunctive prevention and therapy of burn infection due to therapy is not contraindicated.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Effects of Protein Synthesis Inhibitors on the Lethal Action of Kanamycin and Streptomycin
    222 THE JOURNAL OF ANTIBIOTICS, SER. A Nov. 1963 EFFECTS OF PROTEIN SYNTHESIS INHIBITORS ON THE LETHAL ACTION OF KANAMYCIN AND STREPTOMYCIN Hrnosm YA MAKI & NoBuo TAN AKA Institute of Applied Microbiology, University of Tokyo (Received for publication June 11, 1963) It was reported by ANAND and DAv1s 1l that chloramphenicol prevents killing of E.coli by streptomycin when the two antibiotics are added to the bacterial culture concomitantly. ANAND, DAvrs and ARMITAGE 2l demonstrated that chloramphenicol blocks accumulation of BC-streptomycin in bacteria. HuRwITz and RosANo 8l assumed the prerequisite of a strepto­ mycin-induced chloramphenicol-sensitive protein synthesis for the lethal action of strepto­ mycin. They•l also observed that chloramphenicol inhibits intrabacterial accumulation of BC-streptomycin and suggested that streptomycin-induced protein may be a specific transport system (permease). However, if the above assumption 1s correct, the induced protein synthesis appears not to be inhibited by streptomycin itself, although the antibiotic is known to interfere with protein synthesis under a certain conditions. W e5l are interested in the mode of action of kanamycin and like to know whether a similar phenomenon occurs with the lethal action of kanamycin. For the purpose of elucidating these problems, the effects of antibiotics, which inhibit bacterial protein synthesis, on the lethal action of kanamycin and streptomycin were studied and the results are presented in this publication. The antibiotics used include chloramphenicol, erythromycin, mikamycin A, puromycin, blasticidin S and tetracycline. The bactericidal action of both streptomycin and kanamycin was blocked by chloramphenicol, erythromycin, mikamycin A, blasticidin S and tetra­ cycline, but not by puromycin.
    [Show full text]
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]